Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Caris Life Sciences Selects Illumina’s MiSeq® System

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.

Illumina, Inc. has announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris' evidence-based molecular profiling service.

The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina's amplicon-based assay.

Caris Life Sciences' molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information.

Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients.

The addition of next-generation sequencing to Caris' molecular profiling service represents the next step in the natural evolution of this cutting-edge offering.

"We are pleased to be the selected sequencing platform for Caris Life Sciences, an unmatched leader in tumor profiling, whose molecular profiling service has been ordered for more than 40,000 patients to date," said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business.

Posard continued, "This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes."

Caris Life Sciences is one of the few entities to offer next-generation sequencing commercially in their CLIA-accredited laboratory, and will replace its current sequencing technology with Illumina's MiSeq system.

The addition of next-generation sequencing via the MiSeq complements the variety of highly integrated technology platforms already employed by Caris, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR).

Caris' molecular profiling service uses these cutting-edge technologies to comprehensively interrogate the entire cancer biological process - including DNA, RNA, and protein analysis.

"Caris leverages the most clinically relevant technologies and biomarkers to help physicians individualize care. When we choose to add a new technology to our portfolio, we are committed to selecting a best-in-class platform and partner, as evidenced by our selection of Illumina," said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences.

Spalding continued, "After a thorough evaluation of top NGS platforms, Illumina's data quality, simple workflow, and commitment to a collaborative approach were key to our decision to work with them."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Receives FDA 510(k) Clearance for its BeadXpress® Multiplex Analysis System
BeadXpress system is designed for simultaneous detection of multiple analytes in a DNA sample utilizing VeraCode holographic microbead technology.
Tuesday, May 04, 2010
Illumina Announces Scale-Up of Genome Analyzers at the Broad Institute
Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
Friday, November 06, 2009
Illumina Announces Roadmap to Five Million Variants for Next-Generation Whole-Genome Genotyping
Illumina has outlined an ongoing collaboration with leading researchers to select the highest-value markers from the 1000 Genomes Project for GWAS.
Friday, October 23, 2009
Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers
Acquisition expands the capacity of GMI’s recently established Asian Genome Center to 10 Illumina sequencing systems.
Thursday, July 23, 2009
Illumina Announces Personal Genome Sequencing Service
Company has unveiled a service program to provide high-quality personal genome sequencing for consumers.
Friday, June 12, 2009
BGI Expands its Shenzhen and Hong Kong Branches with Addition of 12 Illumina Genome Analyzers
Scale-up of Illumina's sequencing platform increases BGI's total genome analyzer capacity to 29 units.
Tuesday, April 21, 2009
Illumina Announces Scale-Up of its Genome Analyzer Sequencing Technology at the Broad Institute
Broad adds 22 new units to significantly expand its whole-genome sequencing capacity.
Friday, April 17, 2009
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos